ABSTRACT NSC 314622 was found to have a cytotoxicity profile comparable to the topoisomerase I (top1) inhibitors camptothecin (CPT) and saintopin in the National Cancer Institute In Vitro Anticancer Drug Discovery Screen using the COMPARE analysis. In vitro data showed that NSC 314622 induced DNA cleavage in the presence of top1 at micromolar concentrations. Cleavage specificity was different from CPT in that NSC 314622 did not cleave all sites induced by CPT whereas some sites were unique to the NSC 314622 treatment. Top1-induced DNA cleavage was also more stable than cleavage induced by CPT. NSC 314622 did not induce DNA cleavage in the presence of human topoisomerase II. High concentrations of NSC 314622 did not produce detectable DNA unwinding, which suggests that NSC 314622 is not a DNA intercalator. DNA damage analyzed in human breast carcinoma MCF7 cells by alkaline elution showed that NSC 314622 induced proteinlinked DNA single-strand breaks that reversed more slowly than CPT-induced strand breaks. CEM/C2, a CPT-resistant cell line because of a top1 point mutation [Cancer Res 55:1339 -1346 (1995)], was cross-resistant to NSC 314622. These results demonstrate that NSC 314622 is a novel top1-targeted drug with a unique chemical structure.
from DuPont-New England Nuclear (Boston, MA). SV40, c-myc human DNA inserted in pBR322, and oligonucleotides were purchased from GIBCO BRL, the American Type Culture Collection (Rockville, MD), and Midland Certified Reagent (Midland, TX), respectively.
Cell cultures. The MCF7 cells were obtained from Dr. Dominic Scudiero (Developmental Therapeutics Program, National Cancer Institute, Frederick, MD). The CEM/C2 cell line was established as described previously (Fujimori et al., 1995 (Fujimori et al., , 1996 . Cells were maintained in RPMI 1640 (GIBCO BRL, Gaithersburg MD) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA) and 2 mM L-glutamine in a 5% CO 2 incubator at 37°.
Top1-mediated DNA cleavage reactions using end-labeled c-myc DNA, 161-bp plasmid DNA, and the top1 oligonucleotides. The 401-bp DNA fragment from the human c-myc protooncogene includes the junction between the first intron and first exon. It was prepared by PCR using the sense primer (oligo 2671-2692) and the antisense primer (oligo 3052-3072); the numbers in parenthesis refer to the genomic position of the corresponding base in c-myc DNA (Leteurtre et al., 1994) . Single-end labeling was obtained by 32 P-5Ј-end labeling of the sense primer. Twenty picomoles of DNA were incubated for 30 min at 37°with 10 units of T4 polynucleotide kinase and 10 pmol of [␥- 32 P]ATP (approximately 100 Ci) in kinase buffer (70 mM Tris⅐HCl, pH 7.6, 0.1 M KCl, 10 mM MgCl 2 , 5 mM dithiothreitol, and 0.5 mg/ml bovine serum albumin). Reactions were stopped by heat denaturation at 70°for 10 min. Five picomoles of the labeled primer and 10 pmol of the antisense primer (unlabeled) were used for the PCR. Approximately 0.1 g of the c-myc plasmid that had been cleaved with SmaI and SacI was used as a template during the 22 temperature cycle reactions (each cycle: 95°for 1 min, 56°for 1.5 min, and 72°for 2 min). The last extension was for 7 min. DNA was purified using a G-50 quick spin column (Boehringer-Mannheim Biochemicals, Indianapolis, IN). The resulting 401-bp PCR fragment corresponded to the human c-myc DNA region between positions 2671 and 3072, according to the GenBank numbers. This fragment was used to assay top1-induced DNA cleavage by CPT or NSC 314622. Top1 reactions were performed at 30°for 30 min in the presence of CPT or NSC 314622. The same volume of DMSO used in the drug-treated samples was added to the reactions without drug. Reactions were terminated by adding 0.5% SDS followed by digestion with 0.5 mg/ml proteinase K for 60 min at 50°. Reversibility of cleavage complexes was tested by adding 0.5 M NaCl 15 min before terminating the reactions.
The 161-bp fragment from pBluescript SK(Ϫ) phagemid DNA (Stratagene, La Jolla, CA) was cleaved with the restriction endonucleases PvuII and HindIII (New England Biolabs, Beverly, MA) in supplied NE buffer 2 (50-l reactions) for 1 hr at 37°, separated by electrophoresis in a 1% agarose gel made in 1 ϫ TBE buffer. The 161-bp fragment was eluted from the gel slice (centrilutor by Amicon, Beverly, MA) and concentrated in a centricon 50 centrifugal concentrator (Amicon). Approximately 200 ng of the fragment was 3Ј-end labeled at the HindIII site by fill-in reaction with [␣- 32 P]dCTP and 0.5 mM dATP, dGTP, and dTTP, in REact 2 buffer (50 mM Tris⅐HCl, pH 8.0, 100 mM MgCl, and 50 mM NaCl; New England Biolabs) with 0.5 units of DNA polymerase I (Klenow fragment). Labeling reactions were followed by phenol/chloroform extraction and ethanol precipitation. The resulting 161-bp 3Ј-end-labeled DNA fragment was resuspended in water. Aliquots (approximately 50,000 dpm/ reaction) were incubated with top1 at 30°for 15 min in the presence of NSC 314622 or CPT. Reactions were terminated by adding 0.5% SDS. After ethanol precipitation the samples were resuspended in loading buffer (80% formamide, 10 mM sodium hydroxide, 1 mM sodium EDTA, 0.1% xylene cyanol, and 0.1% bromphenol blue, pH 8.0), and separated in a denaturing gel (16% polyacrylamide and 7 M urea) run at 51°. The gel was dried and visualized by using a PhosphorImager and ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
The DNA oligonucleotide with a single top1 cleavage site  synthesized by Midland Certified Reagent) was used to assay top1 sensitivity to CPT and NSC 314622. The 32-mer DNA was labeled at the 3Ј-terminus on the sense strand with [␣-32 P]cordycepin and terminal transferase, as described previously . Aliquots of this oligonucleotide (20,000-50,000 dpm/reaction) were incubated with top1 at 37°for 15 min in the presence of CPT or NSC 314622. Reactions were terminated by adding 0.5% SDS. Samples were denatured by adding four volumes of loading buffer (80% formamide, 10 mM sodium hydroxide, 1 mM sodium EDTA, 0.1% xylene cyanol, and 0.1% bromphenol blue, pH 8.0), and separated in a denaturing gel (16% polyacrylamide and 7 M urea) run at 51°. Top1-mediated cleavage generates a fast migrating DNA band that corresponds to a cleaved (19-mer) product from the uncleaved substrate (33-mer) (see Fig. 5A ). Radioactivity of the cleaved and uncleaved products was quantified using a PhosphorImager and ImageQuant software.
SV40 DNA unwinding assay. Reaction mixtures (10 l final volume) contained 0.3 g supercoiled SV40 DNA in reaction buffer (10 mM Tris⅐HCl, pH 7.5, 50 mM KCl, 5 mM MgCl 2 , 0.1 mM EDTA, and 15 g/ml bovine serum albumin) and 10 units of purified calf thymus top1 (Pommier et al., 1987) . Reactions were performed at 37°f or 30 min and terminated by the addition of 0.5% SDS. Next, 1.1 l of 10ϫ loading buffer (20% Ficol 400; 0.1 M Na 2 EDTA, pH 8.0, 1.0% SDS, and 0.25% bromphenol blue) was added and reactions mixtures were loaded onto a 1% agarose gel made in 1 ϫ TBE buffer. After electrophoresis, DNA bands were stained in 10 g/ml of ethidium bromide and visualized by transillumination with ultraviolet light (300 nm).
Top1-mediated DNA relaxation assays. Reactions were performed in a 10-l final volume at 37°in reaction buffer (see above) with 0.3 g supercoiled SV40 DNA and 1 unit of top1 per reaction. Aliquots were taken at indicated times and stopped with 0.5% SDS (final concentration). Samples were digested with 0.5 mg/ml proteinase K for 15 min at 50°, mixed with 1.1 l of 10 ϫ loading buffer (see above), and subjected to electrophoresis in a 1% agarose gel made in 1 ϫ TBE buffer. The ethidium bromide (0.5 g/ml) stained supercoiled bands were visualized using a Molecular Dynamics FluorImager and quantified with ImageQuant software.
DNA single-strand breaks, measurements by alkaline elution. Human MCF7 breast carcinoma cells were treated with NSC 314622 or CPT for 1 hr. Aliquots were analyzed by alkaline elution (Covey et al., 1989; Bertrand and Pommier, 1995) .
Cytotoxicity assays in human leukemia CEM and CPT-resistant CEM/C2 cells. Exponentially growing CEM and CEM/C2 cells were treated with NSC 314622 or CPT for the times indicated in Table 1 . The cells were counted with a Coulter Electronics (Miami Lake, FL) Counter model ZBI before and 48 hr after beginning of treatment. Growth fraction was calculated relative to control (untreated cells) with control being 1.
Results
COMPARE analysis of NSC 314622. NSC 314622 was selected as a potential top1 inhibitor by COMPARE analysis in the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. The COMPARE algorithm was developed to permit the rapid selection of compounds with similar or novel cytotoxicity relative to established anticancer agents with known mechanisms of action (Boyd and Paull, 1995; Paull et al., 1995) . If the data pattern of an agent of interest correlates well with the data patterns of one or more agents of known mechanism of action, then the hypothesis is that the agent of interest may have the same mechanism of action as those agents of known mechanism. It is always necessary to confirm this hypothesis in the laboratory. If the agent of interest has no good correlation with a set of agents comprising most known biochemical mechanisms of action, the hypothesis is that it has a novel mechanism. This hypothesis is difficult to prove so it remains tentative until the agent's mechanism is actually elucidated in the laboratory.
First, using saintopin, a non-CPT top1 inhibitor (Leteurtre et al., 1994) as a seed in the COMPARE analysis, we found that NSC 314622 was ranked fifth after saintopin and three of its derivatives and that the compounds with highest ranking included 20 CPT derivatives as well as other top1 inhibitors including benzophenanthridines and indolocarbazoles (Pommier, 1998) . This result strongly suggested that NSC 314622 was a potential top1 inhibitor. Fig. 2 shows the cytotoxicity profile of NSC 314622 as a mean graph representation and the similarity between the cytotoxicity profiles of NSC 314622, CPT, and topotecan. A large number of CPT derivatives (33) showed a high Pearson correlation coefficient, 0.84-0.78, with NSC 314622 (Table 1) . The correlation coefficient for NSC 314622 with topotecan was also high, 0.74, but with the unsubstituted CPT, NSC 94600, it was 0.63.
NSC 314622 induces top1-mediated DNA cleavage complexes with a different pattern from CPT. Induction of DNA cleavage in the presence of top1 was tested in a fragment of the human c-myc gene (Fig. 3A) and in the PvuII/HindIII fragment of pBluescript SK(Ϫ) phagemid DNA (Fig. 3B) . A number of cleavage sites detected in the presence of NSC 314622 were also induced by CPT. However, NSC 314622 induced top1 sites that were not observed with CPT, but did not stabilize all the CPT sites, and the relative cleavage intensity of similar sites varied between NSC 314622 and CPT. Top1-induced cleavage in the presence of NSC 314622 was detectable at 0.3 M and increased with increasing drug concentrations up to 100 M. These results confirmed the COMPARE analysis that NSC 314622 is a top1 poison and suggested that the DNA cleavage patterns induced by NSC 314622 exhibited similarities and differences from those of CPT.
Top1 linkage and reversibility of the top1 cleavage complexes induced by NSC 314622. Top1 cleavage complexes are protein linked (Hsiang et al., 1985; Covey et al., 1989) , with top1 covalently linked to the 3Ј-terminus of the DNA break that it generates. Thus, with the use of 5Ј-endlabeled DNA, the labeled strand is expected to become covalently linked to top1. Fig. 4A shows that treatment of 5Ј-end-labeled c-myc DNA with either CPT or NSC 314622 in the presence of top1 resulted in DNA retention at the top of the gel when the proteinase K digestion step was omitted. Treatment with proteinase K released the high molecularweight DNA and generated the cleaved DNA fragments (Fig.  4B ). This result demonstrates that the breaks induced by NSC 314622 are protein linked.
CPT enhances top1 cleavage by stabilizing the cleavable complexes and inhibiting DNA religation (Hsiang et al., 1985) . However, increasing salt concentration can reverse the CPT-induced cleavable complexes, and this method has been used to compare the molecular interactions between CPT derivatives and top1 cleavage complexes (Tanizawa et al., 1995; Valenti et al., 1997) . As shown in Fig. 4B , cleavage sites induced by NSC 314622 and CPT were reversed with NSC, number key to the NCI database (D indicates discrete compound); LHICONC, decimal logarithm of the highest drug concentration tested (molar concentration); Max X, measure of the number of tests that were averaged for this compound; CORR, Pearson coefficient for the seed and the data base compound; and N, number of cell lines common to both the seed and the database compound, which therefore are used in the calculation of the CORR. Stability of the top1 cleavage complexes induced by NSC 314622. We also tested the induction of top1 cleavage complexes using an oligonucleotide containing a single top1 cleavage site (Fig. 5A) . In this system, CPT-induced DNA cleavage was seen as an increase of the 19-mer product, and after 1 hr CPT-induced DNA cleavage decreased. This decrease could be due to inactivation of top1 or CPT lability during the time course of the reaction. NSC 314622 also enhanced top1 cleavage in this oligonucleotide at the same site as CPT. The cleavage complexes induced by NSC 314622 were more persistent than the cleavable complexes induced by CPT (Fig. 5, B and C) .
NSC 314622 inhibits top1-mediated DNA relaxation. Top1 is very efficient at relaxing DNA supercoiling (Champoux, 1990; Wang, 1996) . Relaxation of SV40 DNA by top1 was reduced at every time point by NSC 314622 when compared with the top1-mediated SV40 DNA reactions in the absence of drug (Fig. 6) . Thus, NSC 314622 inhibits top1 catalytic activity.
NSC 314622 does not unwind DNA. Unwinding assay using supercoiled DNA in the presence of top1 is a simple procedure to detect DNA intercalation (Pommier et al., 1987) . In this assay, excess top1 (10 units instead of the 1 unit per reaction shown in Fig. 6 ) is used to compensate for an eventual inhibitory effect of the drug tested in the assay (Pommier et al., 1987) . Fig. 7 shows that NSC 314622 had no detectable effect on top1-mediated relaxation of SV40 DNA. These results suggest that NSC 314622 is not a DNA intercalator up to a concentration of 100 M.
Protein-linked DNA single-strand breaks induced by NSC 314622 in human breast carcinoma MCF7 cells. Drug-induced top1 cleavage complexes were assayed in MCF7 cells by alkaline elution. Typically, in the case of CPT (Covey et al., 1989) , top1 cleavage complexes can be found as DNA single-strand breaks that are detectable only after proteinase digestion of the cell lysates. Fig. 8 shows that 1 M NSC 314622 produced approximately 300 rad-equivalent DNA single-strand breaks and that, as in the case of CPT, these breaks were protein associated (top 1 linked).
Reversal kinetics of DNA single-strand breaks induced by NSC 314622 in MCF7 cells. As shown in Fig. 9,   Fig. 3 . Top1-mediated cleavage induced by NSC 314622. A, The DNA fragment used corresponds to the 5Ј-end-labeled sense strand of the human c-myc protooncogene encompassing the junction of the first intron and the first exon. B, The DNA corresponds to the 3Ј-end-labeled PvuII/ HindIII fragment of pBluescript SK(Ϫ) phagemid DNA. DNA fragments were reacted with top1 in the presence of the indicated concentrations of NSC 314622 or CPT. Reactions were at 30°for 30 min and stopped by adding 0.5% SDS followed by proteinase K digestion. DNA fragments were separated on 7% denaturing polyacrylamide gels. A, Lane G ϩ A: purine ladder; right lane: DNA reacted with 10 M NSC 314622 in the absence of top1. Numbers to the side of the gels, migration position of DNA fragments cleaved at this position in the DNA fragment analyzed. Fig. 4 . Protein linkage and reversibility of the top1 cleavage complexes (DNA breaks and top1-DNA complexes) induced by NSC 314622. The 5Ј-end-labeled c-myc DNA fragment used was the same as the one shown in Fig. 3a . Reactions were performed with top1 in the absence of drug (top1) or in the presence of 10 M CPT (ϩ CPT) or 100 M NSC 314622 (ϩ NSC 314622). After incubation at 30°for 30 min, reactions were stopped with 0.5% SDS with (؉) or without (Ϫ) subsequent digestion with proteinase K (0.5 mg/ml for 60 min at 50°). Reactions (R) were reversed in 0.5 M NaCl for 15 min before addition of 0.5% SDS and proteinase K digestion. The gel picture was cut to show the top of gel (A) with the top 1-linked DNA fragments (black arrow) and the bottom part of the gel (B) with the full size DNA (white arrow) and the top1-mediated DNA cleavage products. G ϩ A, purine ladder after formic acid sequencing of the control DNA. CPT-induced DNA single-strand breaks were completely reversed 30 min after the drug was removed from the cell cultures (Covey et al., 1989; Valenti et al., 1997) , whereas it took more than 1 hr for the NSC 314622-induced DNA singlestrand breaks to reverse. Thus, the DNA single-strand breaks induced by NSC 314622 reversed more slowly than the breaks induced by CPT.
Cytotoxicity of NSC 314622 in a CPT-resistant top1-mutant cell line. CEM/C2 cells are highly resistant to CPT as a result of a mutation of one of the top1 alleles, Asn722Ser (Fujimori et al., 1995) , and inactivation of the other top1 allele(s) (Fujimori et al., 1996) . Table 2 shows that CEM/C2 cells were cross-resistant to NSC 314622, consistent with the possibility that top1 is a cytotoxic target of NSC 314622.
Discussion
DNA topoisomerases are important targets for cancer chemotherapy. Two of the cellular topoisomerases, top2 and top1, are targeted specifically by potent anticancer drugs, although no inhibitor has been reported for the more recently discovered third class of cellular topoisomerases, top3 (Wang, 1996) . Top2 is the target of several of the most effective anticancer drugs to date: the anthracyclines (doxorubicin, daunorubicin, epirubicin, and idarubicin), the epipodophyllotoxins etoposide (VP-16) and teniposide (VM-26), the anthracenediones (mitoxantrone and derivatives), the ellipticines, the acridine amsacrine and the bis-dioxopiperazines, ICRF 187 and 193 [for review, see Pommier (1997) ]. Each of these top2 inhibitors has preferential activity for different cancers. Hence, it is likely that non-CPT top1 inhibitors will exhibit different anticancer activity from camptothecins.
Several methods have been applied to the discovery of novel top1 inhibitors. Biochemical assays with top1 and purified DNA have led to the recent discovery of several novel classes of top1 inhibitors [for recent review see Pommier (1998) ], including actinomycin D (Trask and Muller, 1988; Wassermann et al., 1990) ; morpholinodoxorubicin (Wassermann et al., 1990) ; saintopin (Yamashita et al., 1991; Leteurtre et al. 1994) ; and other benzoanthracenes, nitidine, and other benzophenanthridines (Fang et al., 1993; Larsen et al., 1993) ; indoloquinolinediones (Riou et al., 1991) ; intoplicine (Poddevin et al., 1993) ; indolocarbazoles (Yamashita et al., 1992; Yoshinari et al., 1995) ; and benzimidazoles (Chen et al., 1993; Kim et al., 1996) . Yeast strains with deletion of the top1 gene can also be a useful screening tool because these mutants are selectively resistant to CPT and other top1 poisons (Nitiss and Wang, 1988; Gatto et al., 1996; Nitiss et al., 1997) . A third approach is provided by the National Cancer Institute Anticancer Drug Screen and the COMPARE analysis (Paull et al., 1989; Boyd and Paull, 1995; Paull et al., 1995) . Table 1 provides a summary COMPARE listing for NSC 5) for 30 min at 37°. Reactions were stopped with 0.5% SDS followed by proteinase K digestion and run in 1% agarose gel in TBE buffer. DNA was visualized after staining the gel with ethidium bromide. 14 C]thymidine as described in Materials and Methods and were treated with 0.1 M CPT or 1 M NSC 314622 for 1 hr at 37°. DNA single-strand breaks were assayed by alkaline elution (Covey et al., 1989) with 300 rads (ࠗ); 0.1 M CPT (OE); or 1 M NSC 314622 (f). Proteinassociated (top1-associated) strand breaks were assayed under nondeproteinizing conditions after treatment with 0.1 M CPT (‚) or 1 M NSC 314622 (Ⅺ).
314622. Briefly, the 60 cell-line growth-inhibitory data obtained for NSC 314622 in the screen was correlated in pairs with the growth-inhibitory data for more than 60,000 compounds. The resulting list of NSC numbers and correlation coefficients was sorted by decreasing correlation coefficient. As shown in Table 1 , portions of a list of the top 100 correlations were condensed to a single line if two or more camptothecins came together. Fig. 2 shows the GI50 mean graph (Boyd and Paull, 1995; for NSC 314622. These COMPARE data suggested that NSC 314622 was a top1 inhibitor. We previously used COMPARE to identify a novel top2 inhibitor, NSC 665517 (Gupta et al., 1995a) and to discover that azatoxins, a novel class of top2 inhibitors, exhibited antitubulin activity (Solary et al., 1993) . COMPARE has also been used to identify p-glycoprotein MDR substrates (Lee et al., 1994; Alverez et al., 1995) and new antitubulin agents (Paull et al., 1992) . The recent inclusion of a large number of CPT derivatives in the National Cancer Institute Database and the identification of other tested agents as top1 inhibitors have provided the means to identify novel top1 inhibitors. NSC 314622 is the first top1 inhibitor reported using COMPARE.
Our biochemical assays with purified top1 demonstrated that NSC 314622 is a top1 inhibitor. The cellular data with the top1 mutant and CPT-resistant CEM/C2 cell line (Fujimori et al., 1995 (Fujimori et al., , 1996 also are consistent with the hypothesis that NSC 314622 targets top1 in cells. Top1 inhibition by NSC 314622 exhibits some differences from CPT. First, some of the drug-induced cleavage sites seemed different. Some sites were more intense with NSC 314622, whereas others were more intense with CPT. Such differences may be important in cells because some genes may be more selectively targeted by one compound than the other. Second, the top1 cleavage complexes trapped by NSC 314622 seemed more persistent than those induced by CPT in MCF7-treated cells (Fig. 9 ) and with purified enzyme (Fig. 5) . This might offer an advantage for cancer chemotherapy because the rapid reversibility of the CPT-induced cleavage complexes imposes long infusions of CPTs to achieve maximum activity (Pommier, 1996) . Third, NSC 314622 differs from CPTs in that NSC 314622 is chemically more stable than CPT. At physiological, and even more readily at alkaline pH, the lactone E ring of CPTs is hydrolyzed to the carboxylate form, which has no detectable activity against purified top1 . Thus, it seems that NSC 314622 is a lead compound for developing novel non-CPT top1 inhibitors.
Most of the other non-CPT top1 inhibitors reported to date [see above and, for review, see Pommier (1998) ] are DNA intercalators or minor groove binders. Our unwinding assay data suggested that NSC 314622 did not intercalate into DNA. The fact that the top1 cleavage complexes were not inhibited at high drug concentrations is also consistent with lack of strong DNA intercalation for NSC 314622. 
